News/ News/ R&D Merck turns to cardiovascular pipeline for its post-Keytruda future Phil Taylor atherosclerosis, cardiovascular disease, heart failure, Merck & Co, pulmonary arterial hypertension, R&D 0 Comment For some years industry observers have been asking what Merck & Co can do to reduce its reliance Share X Merck turns to cardiovascular pipeline for its post-Keytruda future https://pharmaphorum.com/news/merck-turns-to-cardiovascular-pipeline-for-its-post-keytruda-future/